CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions

Annals of Surgery

Volumn 241, Issue 3, 2005, Pages 491-496

  Duxbury, Mark S ^a   Matros, Evan ^a   Clancy, Thomas ^a   Bailey, Gerald ^a   Doff, Michael ^a   Zinner, Michael J ^a   Ashley, Stanley W ^a   Maitra, Anirban ^b   Redston, Mark ^a   Whang, Edward E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; ONCOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA IN SITU; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA IN SITU; PANCREAS RESECTION; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, NEOPLASM; CARCINOMA IN SITU; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 20044385743     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000154455.86404.e9     Document Type: Article

References (25)

1. Jemal A, Murray T, Samuels A, Ghafoor A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Zervos EE, Rosemurgy AS, Al Saif O, et al. Surgical management of early-stage pancreatic cancer. Cancer Control. 2004;11:23-31.
3. Duxbury MS, Ito H, Zinner MJ, et al. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene. 2004;23:465-473.
4. Ilantzis C, DeMarte L, Screaton RA, et al. Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia. 2002;4:151-163.
5. Jantscheff P, Terracciano L, Lowy A, et al. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol. 2003;21:3638-3646.
6. Kodera Y, Isobe K, Yamauchi M, et al. Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointestinal cancer; the correlation with degree of differentiation. Br J Cancer. 1993;68:130-136.
7. Ordonez C, Screaton RA, Ilantzis C, et al. Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res. 2000;60:3419-3424.
8. Scholzel S, Zimmermann W, Schwarzkopf G, et al. Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol. 2000;156:595-605.
9. Streuli CH, Gilmore AP. Adhesion-mediated signaling in the regulation of mammary epithelial cell survival. J Mammary Gland Biol Neoplasia. 1999;4:183-191.
10. Yawata A, Adachi M, Okuda H, et al. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. Oncogene. 1998;16:2681-2686.
11. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int. 2000;50:273-279.
12. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003;16:902-912.
13. Mayne KM, Pulford K, Jones M, et al. Antibody By114 is selective for the 90 kD PI-linked component of the CD66 antigen: a new reagent for the study of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1993;83:30-38.
14. Tooze JA, Saso R, Marsh JC, et al. The novel monoclonal antibody By114 helps detect the early emergence of a paroxysmal nocturnal hemoglobinuria clone in aplastic anemia. Exp Hematol. 1995;23:1484-1491.
15. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. New York: Springer-Verlag; 2002.
16. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
17. Duxbury MS, Ito H, Zinner MJ, et al. CEACAM6 gene silencing impairs anoikis resistance and suppresses metastasis of pancreatic adenocarcinoma. J Surg Res. 2003;114:241.
18. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002;62:819-826.
19. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124:619-626.
20. Arvelo F, Poupon MF. [Molecular and cell aspects of the cancer metastasis]. Acta Cient Venez. 2001;52:304-312.
21. Fiucci G, Ravid D, Reich R, et al. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene. 2002;21:2365-2375.
22. Graft JR, Deddens JA, Konicek BW, et al. Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res. 2001;7:1987-1991.
23. Swan EA, Jasser SA, Holsinger FC, et al. Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol. 2003;39:648-655.
24. Zhu Z, Sanchez-Sweatman O, Huang X, et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res. 2001;61:1707-1716.
25. Rojas M, DeMarte L, Screaton RA, et al. Radical differences in functions of closely related members of the human carcinoembryonic antigen gene family. Cell Growth Differ. 1996;7:655-662.